Name: Shaping your brand awareness
Uploaded: 2020-10-14T04:00:00.000Z
Description: In part two of this video series, Paige Velasquez Budde, CEO of Zilker Media, reveals the benefits of shaping your brand awareness.

Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.

Experts Pen 12 Implementable Steps For Addressing Gender Inequity In Academic Dermatology

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.

In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

View

News 

Videos

In part two of this video series, Paige Velasquez Budde, CEO of Zilker Media, reveals the benefits of shaping your brand awareness.

Shaping your brand awareness